{"id":49040,"date":"2025-11-26T16:04:11","date_gmt":"2025-11-26T08:04:11","guid":{"rendered":"https:\/\/flcube.com\/?p=49040"},"modified":"2025-11-26T16:04:12","modified_gmt":"2025-11-26T08:04:12","slug":"fosuns-luvometinib-gets-nmpa-priority-review-for-pediatric-lch","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49040","title":{"rendered":"Fosun&#8217;s Luvometinib Gets NMPA Priority Review for Pediatric LCH"},"content":{"rendered":"\n<p><strong>Fosun Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its marketing application for <strong>luvometinib<\/strong> with <strong>Priority Review status<\/strong> for the treatment of pediatric patients aged <strong>2 years and older<\/strong> with <strong>Langerhans Cell Histiocytosis (LCH)<\/strong>, expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Luvometinib (MEK1\/2 inhibitor)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Fosun Pharma (600196.SH; 2196.HK)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Marketing authorization with <strong>Priority Review<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pediatric LCH (age \u22652 years)<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>May\u202f2025: Adult LCH\/histiocytic neoplasms; Pediatric\/adolescent NF1\u2011PN<\/td><\/tr><tr><td><strong>Special Designation<\/strong><\/td><td>Included in <strong>SPARK project<\/strong> (Sep\u202f2025) for pediatric anti\u2011tumor drug R&amp;D<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Selective <strong>MEK1\/2 inhibitor<\/strong> that blocks MAPK pathway signaling<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First MEK inhibitor approved in China for <strong>LCH and histiocytic neoplasms<\/strong>; extends to pediatric population<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Oral tablet for pediatric use<\/li>\n\n\n\n<li><strong>Clinical Path:<\/strong> Phase\u202fIII trial for <strong>pediatric low\u2011grade glioma<\/strong> initiated <strong>July\u202f2025<\/strong>; SPARK program inclusion accelerates review<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-pipeline\">Clinical Development Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Indication<\/th><th>Status<\/th><th>Next Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>LCH Pediatric<\/strong><\/td><td>Langerhans Cell Histiocytosis (age \u22652)<\/td><td>Priority Review (Nov\u202f2025)<\/td><td>Approval expected <strong>Q2\u202f2026<\/strong><\/td><\/tr><tr><td><strong>NF1\u2011PN<\/strong><\/td><td>Plexiform neurofibromas (NF1)<\/td><td>Approved (May\u202f2025)<\/td><td>Commercial launch Q4\u202f2025<\/td><\/tr><tr><td><strong>Low\u2011grade glioma<\/strong><\/td><td>Pediatric brain tumors<\/td><td>Phase\u202fIII initiated (Jul\u202f2025)<\/td><td>Data readout <strong>H2\u202f2027<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China LCH Prevalence<\/strong><\/td><td>~500\u2011800 pediatric patients<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Chemotherapy (cladribine, cytarabine); no approved targeted therapy<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Expected \u00a5200,000\u2011300,000\/year (aligns with rare disease biologics)<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>\u00a580\u2011120\u202fmillion<\/strong> (US$11\u201116\u202fmillion) by 2028<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>60\u201170% of eligible pediatric patients<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td>Only MEK inhibitor in China for LCH; SPARK program provides regulatory fast\u2011track<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SPARK Program:<\/strong> Inclusion provides <strong>expedited review<\/strong>, <strong>pediatric\u2011specific guidance<\/strong>, and potential <strong>pricing benefits<\/strong> under China\u2019s rare disease policy<\/li>\n\n\n\n<li><strong>Reimbursement Path:<\/strong> Rare disease designation likely to secure <strong>NRDL inclusion<\/strong> within 12\u201118 months post\u2011approval<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Fosun\u2019s <strong>pediatric oncology portfolio<\/strong> and demonstrates capability in ultra\u2011rare disease development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding luvometinib\u2019s regulatory review, market potential, and SPARK program benefits. Actual results may differ materially due to risks including NMPA approval timelines, pricing negotiations, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600196_20251122_PHY4.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20251122_PHY4.\"><\/object><a id=\"wp-block-file--media-a56009e1-d96a-4ce4-bccd-d41ca867fcc0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600196_20251122_PHY4.pdf\">600196_20251122_PHY4<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600196_20251122_PHY4.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a56009e1-d96a-4ce4-bccd-d41ca867fcc0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49042,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,159,893,38,892,33],"class_list":["post-49040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-fosun-pharmaceutical","tag-hkg-2196","tag-market-approval-filings","tag-sha-600196","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun&#039;s Luvometinib Gets NMPA Priority Review for Pediatric LCH - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for luvometinib with Priority Review status for the treatment of pediatric patients aged 2 years and older with Langerhans Cell Histiocytosis (LCH), expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49040\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun&#039;s Luvometinib Gets NMPA Priority Review for Pediatric LCH\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for luvometinib with Priority Review status for the treatment of pediatric patients aged 2 years and older with Langerhans Cell Histiocytosis (LCH), expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49040\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T08:04:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T08:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun&#8217;s Luvometinib Gets NMPA Priority Review for Pediatric LCH\",\"datePublished\":\"2025-11-26T08:04:11+00:00\",\"dateModified\":\"2025-11-26T08:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2607.webp\",\"keywords\":[\"Cancer\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Market approval filings\",\"SHA: 600196\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49040#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49040\",\"name\":\"Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2607.webp\",\"datePublished\":\"2025-11-26T08:04:11+00:00\",\"dateModified\":\"2025-11-26T08:04:12+00:00\",\"description\":\"Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for luvometinib with Priority Review status for the treatment of pediatric patients aged 2 years and older with Langerhans Cell Histiocytosis (LCH), expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49040\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2607.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2607.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49040#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun&#8217;s Luvometinib Gets NMPA Priority Review for Pediatric LCH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for luvometinib with Priority Review status for the treatment of pediatric patients aged 2 years and older with Langerhans Cell Histiocytosis (LCH), expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49040","og_locale":"en_US","og_type":"article","og_title":"Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH","og_description":"Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for luvometinib with Priority Review status for the treatment of pediatric patients aged 2 years and older with Langerhans Cell Histiocytosis (LCH), expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.","og_url":"https:\/\/flcube.com\/?p=49040","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T08:04:11+00:00","article_modified_time":"2025-11-26T08:04:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49040#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49040"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun&#8217;s Luvometinib Gets NMPA Priority Review for Pediatric LCH","datePublished":"2025-11-26T08:04:11+00:00","dateModified":"2025-11-26T08:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49040"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49040#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp","keywords":["Cancer","Fosun Pharmaceutical","HKG: 2196","Market approval filings","SHA: 600196","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49040#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49040","url":"https:\/\/flcube.com\/?p=49040","name":"Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49040#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49040#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp","datePublished":"2025-11-26T08:04:11+00:00","dateModified":"2025-11-26T08:04:12+00:00","description":"Fosun Pharma (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for luvometinib with Priority Review status for the treatment of pediatric patients aged 2 years and older with Langerhans Cell Histiocytosis (LCH), expanding the MEK inhibitor\u2019s reach into ultra\u2011rare pediatric oncology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49040#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49040"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49040#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp","width":1080,"height":608,"caption":"Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49040#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun&#8217;s Luvometinib Gets NMPA Priority Review for Pediatric LCH"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2607.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49040"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49040\/revisions"}],"predecessor-version":[{"id":49043,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49040\/revisions\/49043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49042"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}